Evidence map›Paper›PMID 32548281›Full record

ReviewTomography (Ann Arbor, Mich.)2020

Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network.

Ella F Jones, John M Buatti, Hui-Kuo Shu, Richard L Wahl, Brenda F Kurland, Hannah M Linden, David A Mankoff, Daniel L Rubin, Darrell Tata, Robert J Nordstrom and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Tomography (Ann Arbor, Mich.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ella F JonesSchool of Medicine, University of California San Francisco, San Francisco, CA.
John M BuattiCarver College of Medicine, The University of Iowa, Iowa City, IA.
Hui-Kuo ShuWinship Cancer Institute, Emory University, Atlanta, GA.
Richard L WahlSchool of Medicine, Washington University, St. Louis, MO.
Brenda F KurlandDepartment of Biostatistics, University of Pittsburgh, Pittsburgh, PA.
Hannah M LindenSchool of Medicine, University of Washington, Seattle, WA.
David A MankoffPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Daniel L RubinSchool of Medicine, Stanford University, Stanford, CA.
Darrell TataCancer Imaging Program, National Cancer Institute, Bethesda, MD.
Robert J NordstromCancer Imaging Program, National Cancer Institute, Bethesda, MD.
Lubomir HadjiyskiDepartment of Radiology, University of Michigan, Ann Arbor, MI.
Matthias HoldhoffSidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, MD; and.
Lawrence H SchwartzIrving Medical Center, Columbia University, New York Presbyterian Hospital, New York, NY.

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Graph-Based Medical Image Segmentation in 3D and 4DR01EB004640 · NIBIB · UNIVERSITY OF IOWA · PI BUATTI, JOHN M, SONKA, MILAN · 2006 to 2022
$6.1M
Multi-Modality Quantitiative Imaging for Evaluation of Response to Cancer TherapyU01CA140204 · NCI · JOHNS HOPKINS UNIVERSITY · PI DU, YONG, SOLNES, LILJA · 2011 to 2022
$6.1M
Advanced PET/CT Imaging for Improving Clinical TrialsU01CA148131 · NCI · UNIVERSITY OF WASHINGTON · PI KINAHAN, PAUL E., LINDEN, HANNAH M · 2010 to 2019
$6.0M
Quantitative Imaging to Assess Response in Cancer Therapy TrialsU01CA140206 · NCI · UNIVERSITY OF IOWA · PI BUATTI, JOHN M, CASAVANT, THOMAS L. · 2010 to 2019
$5.8M
Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment TrialsR01CA132870 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M., NEWITT, DAVID C · 2008 to 2019
$4.8M
Dedicated breast PET and MRI for characterization of breast cancer and its response to therapyR01CA227763 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Natsuko Onishi Yamashita · 2019 to 2026
$3.6M
Quantitative Imaging for Assessing Breast Cancer Response to TreatmentU01CA225427 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HYLTON-WATSON, NOLA M. · 2018 to 2022
$3.2M
Quantitative MRSI to predict early response to SAHA therapy in new GBM managementU01CA172027 · NCI · EMORY UNIVERSITY · PI BARKER, PETER B, HU, XIAOPING P · 2013 to 2017
$3.2M
Qualification and Deployment of Imaging Biomarkers of Cancer Treatment ResponseU01CA190214 · NCI · STANFORD UNIVERSITY · PI RUBIN, DANIEL L · 2015 to 2020
$3.1M
Biomarker-Based Tools for Treatment Response Decision Support of Bladder CancerU01CA232931 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALVA, AJJAI SHIVARAM, HADJIYSKI, LUBOMIR M · 2019 to 2024
$3.1M
NCI NIH HHS P30 CA006973NCI NIH HHS R01 CA132870NCI NIH HHS R01 CA227763NCI NIH HHS U01 CA140204NCI NIH HHS U01 CA140206NCI NIH HHS U01 CA140207NCI NIH HHS U01 CA140230NCI NIH HHS U01 CA142555NCI NIH HHS U01 CA148131NCI NIH HHS U01 CA151235NCI NIH HHS U01 CA172027NCI NIH HHS U01 CA179106NCI NIH HHS U01 CA187947NCI NIH HHS U01 CA190214NCI NIH HHS U01 CA225427NCI NIH HHS U01 CA232931NCI NIH HHS U01 CA242879NIBIB NIH HHS R01 EB004640
6 · The paper itself

Abstract

The Clinical Trial Design and Development Working Group within the Quantitative Imaging Network focuses on providing support for the development, validation, and harmonization of quantitative imaging (QI) methods and tools for use in cancer clinical trials. In the past 10 years, the Group has been working in several areas to identify challenges and opportunities in clinical trials involving QI and radiation oncology. The Group has been working with Quantitative Imaging Network members and the Quantitative Imaging Biomarkers Alliance leadership to develop guidelines for standardizing the reporting of quantitative imaging. As a validation platform, the Group led a multireader study to test a semi-automated positron emission tomography quantification software. Clinical translation of QI tools cannot be possible without a continuing dialogue with clinical users. This article also highlights the outreach activities extended to cooperative groups and other organizations that promote the use of QI tools to support clinical decisions.

Indexed as

Clinical Trials as TopicDiagnostic ImagingNeoplasmsRadiation OncologyClinical Trials, Phase III as TopicHumansPositron-Emission TomographyRandomized Controlled Trials as TopicTomography, X-Ray ComputedClinical Trial Design and Development (CTDD)Quantitative Imaging Network (QIN)

Identifiers

PMID32548281
PMCPMC7289239

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.